Thrombopoietin is ineffective in a mouse model of motor neuron disease

References

• Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CW, Alexander DD, et al. Motor neuron degeneration in mice that express a human Cu/Zn superoxide dismutase mutation. Science. 1994; 264: 1772–5
   PubMed Web of Science ®Google Scholar
• Schwartz G. American Spinal Injury Association 29th Annual Meeting Vol. 26. Miami, 2003:S11–48.
   Google Scholar
• Kakumitsu H, Kamezaki K, Shimoda K, Karube K, Haro T, Numata A, et al. Transgenic mice overexpressing murine thrombopoietin develop myelofibrosis and osteosclerosis. Leukemia Research. 2005; 29: 761–9
   PubMed Web of Science ®Google Scholar
• Dominguez V, Govezensky T, Gevorkian G, Larralde C. Low platelet counts alone do not cause bleeding in an experimental immune thrombocytopenic purpura in mice. Haematologica. 2003; 88: 679–87
   PubMed Web of Science ®Google Scholar
• Pagano M, Gauvreau K. Principles of Biostatistics. Wadsworth, Inc, Belmont 1993
   Google Scholar
• Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet. 2001; 28: 131–8
   PubMed Web of Science ®Google Scholar
• Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood. 2002; 100: 3495–503
   PubMed Web of Science ®Google Scholar
• Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motor neurons against ischemic death. Nat Genet. 2003; 34: 383–94
   PubMed Web of Science ®Google Scholar
• Kaushansky K. Thrombopoietin. New England Journal of Medicine. 1998; 339: 746–54
   PubMed Web of Science ®Google Scholar
• Marx RE. Platelet-rich plasma: evidence to support its use. Journal of Oral and Maxillofacial Surgery. 2004; 62: 489–96
   PubMed Web of Science ®Google Scholar
• Gao W, Shinsky N, Ingle G, Beck K, Elias KA, Powell-Braxton L. IGF-I deficient mice show reduced peripheral nerve conduction velocities and decreased axonal diameters and respond to exogenous IGF-I treatment. J Neurobiol. 1999; 39: 142–52
   PubMedGoogle Scholar
• Caroni P, Schneider C, Kiefer M, Zapf J. Role of muscle insulin-like growth factors in nerve sprouting: suppression of terminal sprouting in paralyzed muscle by IGF-binding protein. J Cell Biol. 1994; 125: 893–902
   PubMed Web of Science ®Google Scholar
• Thal L. Neurotrophic factors. Progress in Brain Research, J Klein, K Loffelholz. Elsevier Science, New York 1996; 109: 327–30
   Google Scholar
• Storkebaum E, Lambrechts D, Dewerchin M, Moreno-Murciano MP, Appelmans S, Oh H, et al. Treatment of motor neuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci. 2005; 8: 85–92
   PubMed Web of Science ®Google Scholar
• Apfel S. Neurotrophic factor therapy: prospects and problems. Clin Chem Lab Med. 2001; 39: 351–5
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Scheffler M, Smith BN, Parton MJ, Cudkowicz ME, Andersen PM, Hayden DL, et al. Ciliary neurotrophic factor genotype does not influence clinical phenotype in amyotrophic lateral sclerosis. Annals of Neurology. 2003; 54: 130–4
   PubMed Web of Science ®Google Scholar
• Mitchell JD, Wokke JH, Borasio GD. Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2002; 3: D002064C
   Google Scholar
• Janczewska-Kazek E, Marek B, Kajdaniuk D, Borgiel-Marek H. Effects of interferon-alpha and ribavirin treatment on serum levels of transforming growth factor B1, vascular endothelial growth factor, and basic fibroblast growth factor in patients with chronic hepatitis C. World J of Gastroenterol. 2006; 12: 961–5
   PubMed Web of Science ®Google Scholar
• Cronin S, Greenway MJ, Ennis S, Kieran D, Green A, Prehn JH, et al. Elevated serum angiogenin levels in ALS. Neurology. 2006; 67: 1833–6
   PubMed Web of Science ®Google Scholar
• Gurney M, Cutting F, Zhai P, Doble A, Taylor CP, Andrus PK, et al. Benefit of vitamin E, riluzole and gabapentin in a transgenic model of familial ALS. Annals of Neurology. 1996; 39: 147–57
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group. N Engl J Med. 1994; 330: 585–91
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh P, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996; 347: 1425–31
   PubMed Web of Science ®Google Scholar
• Miller RG, Moore DH, Gelinas DF, Dronsky V, Mendoza M, Barohn RJ, et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology. 2001; 56: 843–8
   PubMed Web of Science ®Google Scholar
• Klivenyi P, Ferrante R, Matthews R. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Mat Med. 1999; 5: 347–50
   Google Scholar
• Shefner JM, Cudkowicz ME, Schoenfeld D, Conrad T, Taft J, Chilton M, et al. A clinical trial of creatine in amyotrophic lateral sclerosis. Neurology. 2004; 63: 1656–61
   PubMed Web of Science ®Google Scholar
• Drachman D, Frank K, Dykes-Hoberg M, Teismann P, Almer G, Przedborski S, et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Annals of Neurology. 2002; 52: 771–8
   PubMed Web of Science ®Google Scholar
• Cudkowicz M, Shefner J, Schoenfeld D, Zhang H, Andreasson KI, Rothstein JD, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Annals of Neurology. 2006; 60: 22–31
   PubMed Web of Science ®Google Scholar